TABLE 2.

Cancer disease and pain characteristics, and their association with initial pain intensity (n=371)

Variable	n (%)	Initial pain intensity (iPI)			P
		Mean ± SD	Median	Q1–Q3
Cancer characteristics
Cancer diagnosis
Head and neck	92 (24.8)	5.73±2.22	6	5–7	0.008
Lung	10 (2.7)	5.20±2.25	4.5	4–7
Gastrointestinal	82 (22.1)	5.62±2.69	6	4–7
Breast	43 (11.6)	5.30±3.07	6	2–8
Genitourinary	79 (21.3)	5.70±2.31	6	5–7
Other	65 (17.5)	4.26±2.91	4	2–7
Metastatic disease
No	108 (29.1)	4.74±2.84	5	2–7	0.003
Yes	263 (70.9)	5.64±2.48	6	4–7
Bone metastases
No	242 (65.2)	5.19±2.69	6	3–7	0.059
Yes	129 (34.8)	5.73±2.46	6	4–7
Palliative treatment goal
No	195 (52.6)	4.87±2.83	6	2–7	<0.0001
Yes	176 (47.4)	5.94±2.24	6	5–7
Surgery
No	259 (69.8)	5.39±2.68	6	4–7	0.922
Yes	112 (30.2)	5.36±2.49	6	4–7
Chemotherapy
No	204 (55.0)	5.21±2.78	6	3–7	0.176
Yes	167 (45.0)	5.58±2.41	6	4–7
Radiotherapy
No	195 (52.6)	5.11±2.92	6	2–7	0.038
Yes	176 (47.4)	5.67±2.22	6	4.5–7
Cancer pain characteristics
Nociceptive visceral
No	259 (69.8)	5.29±2.64	6	4–7	0.349
Yes	112 (30.2)	5.57±2.58	6	4–7
Nociceptive soft tissue
No	153 (41.2)	5.52±2.47	6	3–7	0.216
Yes	218 (58.8)	5.57±2.58	6	4–7
Nociceptive bone pain
No	222 (59.8)	5.18±2.67	6	3–7	0.070
Yes	149 (40.2)	5.68±2.52	6	4–7
NeuP (DN4-positive)
No	210 (56.6)	4.73±2.82	5	2–7	<0.0001
Yes	161 (43.4)	6.22±2.05	6	5–8
NeuP (DN4-positive) or clinically mixed
No	84 (22.6)	4.63±2.83	6	2–7	0.003
Yes	287 (77.4)	5.60±2.52	6	4–7
Episodic incident
No	151 (40.7)	5.43±2.65	6	4–7	0.747
Yes	220 (59.3)	5.34±2.60	6	4–7
Episodic breakthrough
No	212 (57.1)	5.17±2.77	6	3–7	0.066
Yes	159 (42.9)	5.66±2.38	6	4–7
Adjuvant analgesics
None	161 (43.4)	4.87±2.79	6	2–7	0.001
≥ 1	210 (56.6)	5.77±2.42	6	4–7

NeuP Neuropathic pain